Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Beijing Wantai Biological Pharmacy Enterprise Co's Marketable Securities for the quarter that ended in Jun. 2026 was ¥1,563 Mil.
Beijing Wantai Biological Pharmacy Enterprise Co's annual Marketable Securities
increased
from Dec. 2023 (¥2,055 Mil) to Dec. 2024 (¥2,510 Mil) but then
declined
from Dec. 2024 (¥2,510 Mil) to Dec. 2025 (¥1,447 Mil).
Beijing Wantai Biological Pharmacy Enterprise Co (SHSE:603392) Marketable Securities Explanation
Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.
Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".
Beijing Wantai Biological Pharmacy Enterprise Co Marketable Securities Related Terms
Beijing Wantai Biological Pharmacy Enterprise Co Marketable Securities Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beijing Wantai Biological Pharmacy Enterprise Co Marketable Securities Chart
Beijing Wantai Biological Pharmacy Enterprise Co Annual Data
What does a Marketable Securities of ¥1,563 Mil mean?
Beijing Wantai Biological Pharmacy Enterprise Co (SHSE:603392) has a Marketable Securities of ¥1,563 Mil as of Jun. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Beijing Wantai Biological Pharmacy Enterprise Co and its competitors.
Is Beijing Wantai Biological Pharmacy Enterprise Co's Marketable Securities too high?
Beijing Wantai Biological Pharmacy Enterprise Co's current Marketable Securities is ¥1,563 Mil. Overall, Beijing Wantai Biological Pharmacy Enterprise Co has a GF Score™ of 54/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Beijing Wantai Biological Pharmacy Enterprise Co's Marketable Securities compare to VRTX and REGN?
Beijing Wantai Biological Pharmacy Enterprise Co's Marketable Securities of ¥1,563 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Beijing Wantai Biological Pharmacy Enterprise Co and its competitors. Beijing Wantai Biological Pharmacy Enterprise Co's current Marketable Securities is ¥1,563 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beijing Wantai Biological Pharmacy Enterprise Co stock overvalued right now?
Based on GuruFocus' analysis, Beijing Wantai Biological Pharmacy Enterprise Co (SHSE:603392) is currently considered Possible Value Trap. The stock's GF Value™ is ¥49.86, compared to a current price of ¥27.67 — trading 44.5% below its estimated fair value. The current Marketable Securities is ¥1,563 Mil. Beijing Wantai Biological Pharmacy Enterprise Co's overall GF Score™ is 54/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Beijing Wantai Biological Pharmacy Enterprise Co (SHSE:603392), the current Marketable Securities is ¥1,563 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Beijing Wantai Biological Pharmacy Enterprise Co (SHSE:603392) Overvalued in 2026?
Based on GuruFocus' analysis, Beijing Wantai Biological Pharmacy Enterprise Co stock appears to be undervalued.
The current stock price of ¥27.67 is trading 44.5% below its estimated GF Value™ of ¥49.86.
GuruFocus considers Beijing Wantai Biological Pharmacy Enterprise Co to be Possible Value Trap.
Key valuation signals for SHSE:603392:
Marketable Securities: ¥1,563 Mil
GF Value™: ¥49.86 vs. price of ¥27.67 (44.5% below fair value)
No single metric tells the full story. See the SHSE:603392 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Beijing Wantai Biological Pharmacy Enterprise Co Ltd is engaged in research, development, production, and sales of in vitro diagnostic reagents, instruments, and vaccines. The company has two segments: Diagnostic and Vaccine. The Diagnostic segment develops and sells in vitro diagnostic reagents such as ELISA, colloidal gold, biochemical, and chemiluminescent kits, along with instruments including chemiluminescent analyzers, fluorescent analyzers, and nucleic acid purification systems. The Vaccine segment focuses on products like the hepatitis E vaccine, the bivalent HPV vaccine, and the nasal spray COVID-19 vaccine. It generates the majority of its revenue from the Diagnostic segment.
54GF Score
Get the complete analysis for SHSE:603392
Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603392 has been successfully added to your 
